Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line

Toxicology and Applied Pharmacology

Volumn 183, Issue 2, 2002, Pages 83-91

  Romiti, Nadia ^a   Tramonti, Gianfranco ^a   Chieli, Elisabetta ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Calcitriol; Cyclosporin A; HK 2 cells; MDR 1; P glycoprotein; Proximal tubules

Indexed keywords

ALDOSTERONE; CALCITRIOL; CIMETIDINE; CYCLOSPORIN A; DEXAMETHASONE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; N (2 FLUORENYL)ACETAMIDE; PROGESTERONE; RHODAMINE 123; THROMBOCYTE ACTIVATING FACTOR; TRIMETHOPRIM; VERAPAMIL;

ARTICLE; BIOACCUMULATION; CELL IMMORTALIZATION; CELL MEMBRANE TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CICONIIFORMES;

EID: 0036406826     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-008X(02)99461-5     Document Type: Article

References (42)

1. Bello-Reuss, E., Ernest, S., Holland, O. B., and Hellmich, M. R. (2000). Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell. Physiol. 278, C1256-1265.
2. Bosch, I., and Croop, J. (1996). P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta 1288, F37-F54.
3. Capella, M. A., Orind, M., Morales, M. M., Rumjanek, V. M., and Lopes, A. G. (1999). Expression of functionally P-glycoprotein in MA104 kidney cells. Z. Naturforsch. [C ] 54, 119-127.
4. Chieli, E., Santoni-Rugiu, E., Cervelli, F., Sabbatini, A., Petrini, M., Romiti, N., Paolicchi, A., and Tongiani, R. (1994). Differential modulation of P-glycoprotein expression by dexamethasone and 3-methylcholanthrene in rat hepatocyte primary cultures. Carcinogenesis 15, 335-341.
5. Collett, A., Higgs, N. B., Sims, E., Rowland, M., and Warhurst, G. (1999). Modulation of the permeability of (H)2 receptor antagonist cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288, 171-178.
6. Decorti, G., Peloso, I., Favarin, D., Klugmann, F. B., Candussio, L., Crivellato, E., Mallardi, F., and Baldini, L. (1998). Handling of doxorubicin by the LLC-PK1 kidney epithelial cell line. J. Pharmacol. Exp. Ther. 286, 525-530.
7. Del Moral, R. G., Olmo, A., Aguilar, M., and O'Valle, F. (1998). P-glycopro-ein: A new mechanism to control drug-induced nephrotoxicity. Exp. Nephrol. 6, 89-97.
8. 1 cells. Br. J. Pharmacol. 117, 1139-1144.
9. Dutt, A., Priebe, T. S., Teeter, L. D., Kuo, M. T., and Nelson, J. A. (1992). Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J. Pharmacol. Exp. Ther. 261, 1222-1230.
10. El Rouby, S., Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R., and Newcomb, E. W. (1993). p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82, 3452-3459.
11. Ernest, S., and Bello-Reuss, E. (1999). Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J. Am. Soc. Nephrol. 10, 2306-2313.
12. Ernest, S., and Bello-Reuss, E. (1998). P-glycoprotein functions and substrates: Possible roles of MDR1 gene in the kidney. Kidney Int. 53, S-11-S-17.
13. 3 is an inhibitor but not a substrate of MDR1 P-glycoprotein in human proximal tubule cells. J. Am. Soc. Nephrol. 9, 564A.
14. Ernest, S., Rajaraman, S., Megyesi, J., and Bello-Reuss, E. (1997). Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 77, 284-289.
15. Fardel, O., Lecureur, V., and Guillouzo, A. (1993). Regulation by dexamethasone of P-glycoprotein expression in cultered rat hepatocytes. FEBS Lett. 327, 189-193.
16. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., and Pastan, I. (1987). Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84, 265-269.
17. Gant, T. W., Silverman, J. A., Bisgaard, H. C., Burt, R. K., Marino, P. A., and Thorgeirsson, S. S. (1991). Regulation of 2-acetylaminofluorene- and 3-methylcholanthrene-mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol. Carcinog. 4, 499-509.
18. Gottesman, M. M., and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62, 385-427.
19. Hauser, I. A., Koziolek, M., Hopfer, U., and Thévenod, F. (1998). Therapeutic concentrations of cyclosporine A but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int. 54, 1139-1149.
20. Ichikawa-Haraguchi, M., Sumizawa, T., Yoshimura, A., Furukawa, T., Hiramoto, S., Sugita, M., and Akiyama, S. (1993). Progesterone and its metabolites: The potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland. Biochim. Biophys. Acta 1158, 201-208.
21. Johnstone, R. W., Ruefli, A. A., and Smyth, M. J. (2000). Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci. 25, 1-6.
22. Lecureur, V., Guillouzo, A., and Fardel, O. (1996). Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Carcinogenesis 17, 1157-1160.
23. Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., von Hoff, D. D., and Roninson, I. B. (1990). Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87, 7160-7164.
24. Noris, M., Perico, N., Macconi, D., Nanni, V., Dadan, J., Peterlongo, F., and Remuzzi, G. (1990). Renal metabolism and urinary excretion of platelet-activating factor in the rat. J. Biol. Chem. 265, 19414-19419.
25. Peterson, G. (1977). A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83, 346-356.
26. Racusen, L. C., Monteil, C., Sgrignoli, A., Lucskay, M., Marouillat, S., Rhim, J. G., and Morin, J. P. (1997). Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J. Lab. Clin. Med. 129, 318-329.
27. Ryan, M. J., Johnson, G., Kirk, J., Fuerstenberg, S. M., Zager, R. A., and Torok-Storb, B. (1994). HK-2: An immortalized proximal tubule ephithelial cell line from normal adult human kidney. Kidney Int. 45, 48-57.
28. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., and Komano, T. (1993). Human P-glycoprotein transports cyclosporine A and FK506. J. Biol. Chem. 268, 6077-6080.
29. Safa, A. R. (1988). Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. Natl. Acad. Sci. USA 85, 7187-7191.
30. Sanchez-Crespo, M., Inarrea, P., Alvarez, V., Alonso, F., Egido, J., and Hernaldo, L. (1983). Presence in normal human urine of a hypotensive and platelet-activating phospholipid. Am. J. Physiol. 244, F706-F711.
31. Santoni-Rugiu, E., and Silverman, J. A. (1997). Functional characterization of the rat mdr 1b encoded P-glycoprotein: Not all inducing agents are substrates. Carcinogenesis 18, 2255-2263.
32. Silverman, J. A., and Schrenk, D. (1997). Expression of the multidrug resistance genes in the liver. FASEB J. 11, 308-313.
33. Silverman, J. A., and Thorgeirsson, S. S. (1995). Regulation and function of the multidrug resistance genes in liver. In Progress in Liver Diseases (Ockner, R. K., and Boyer, J. L., Eds.), Vol. XIII, pp. 101-123. Saunders, Philadelphia.
34. Smit, J. J. M., Schinkel, A. H., Mol, C. A. A. M., Majoor, D., Mooi, W. J., Jongsma, A. P. M., Lincke, C. R., and Borst, P. (1994). Tissue distribution of the human MDR3 P-glycoprotein. Lab. Invest. 71, 638-649.
35. Somogyi, A. (1996). Renal transport of drugs: Specificity and molecular mechanisms. Clin. Exp. Pharmacol. Physiol. 23, 986-989.
36. Tanigawara, Y. (2000). Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 22, 137-140.
37. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738.
38. Tramonti, G., Romiti, N., Norpoth, M., and Chieli, E. (2001). P-glycoprotein in HK-2 proximal tubule cell line. Renal Failure 23, 331-337.
39. Twentyman, P. R. (1992). Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43, 109-117.
40. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T., and Hori, R. (1992). Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267, 24248-24252.
41. Wong, H., Anderson, W. D., Cheng, T., and Riabowol, K. T. (1994). Monitoring mRNA expression by polymerase chain reaction: The "primer-dropping" method. Anal. Biochem. 223, 251-258.
42. Yu, D. K. (1999). The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 39, 1203-1211.